
06/06/2025
Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal
The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based drugs for inflammatory conditions....
https://openexo.com/feed/item/cullinan-doubles-down-on-bispecifics-for-autoimmune-disease-with-genrix-deal?a=moon-auto-multiverse
The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based dru...